{"organizations": [], "uuid": "511bee40e5a9e7522194c053ad3a9917718eee32", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-synlogic-receives-fast-track-desig/brief-synlogic-receives-fast-track-designation-for-synb1618-a-synthetic-biotic-medicine-for-treatment-of-phenylketonuria-idUSFWN1S20LP", "country": "US", "domain_rank": 408, "title": "BRIEF-Synlogic Receives Fast-Track Designation For Synb1618, A Synthetic Biotic Medicine For Treatment Of Phenylketonuria", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-25T14:16:00.000+03:00", "replies_count": 0, "uuid": "511bee40e5a9e7522194c053ad3a9917718eee32"}, "author": "", "url": "https://www.reuters.com/article/brief-synlogic-receives-fast-track-desig/brief-synlogic-receives-fast-track-designation-for-synb1618-a-synthetic-biotic-medicine-for-treatment-of-phenylketonuria-idUSFWN1S20LP", "ord_in_thread": 0, "title": "BRIEF-Synlogic Receives Fast-Track Designation For Synb1618, A Synthetic Biotic Medicine For Treatment Of Phenylketonuria", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "synthetic biotic medicine for treatment of phenylketonuria", "sentiment": "negative"}, {"name": "medicine for treatment of phenylketonuria reuters staff    synlogic inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 25 (Reuters) - Synlogic Inc:\n* SYNLOGIC RECEIVES FAST-TRACK DESIGNATION FOR SYNB1618, A SYNTHETIC BIOTICâ„¢ MEDICINE FOR THE TREATMENT OF PHENYLKETONURIA\n* SYNLOGIC INC - PHASE 1/2A CLINICAL STUDY OF SYNB1618 EXPECTED TO REPORT INTERIM DATA IN 2018 Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-04-25T14:16:00.000+03:00", "crawled": "2018-04-25T14:30:46.012+03:00", "highlightTitle": ""}